Nasdaq
$0.3989▲ 1.19%vs prev close
🔒 Quotes & buy pressure are MAX onlySee plans
Market cap $22.1MShares out 55.5M sh
Chart
Filings & news by date
Hover (PC) or tap (mobile) a candle to see that day only
Filings
10- 10.9After-hours26.10.10 05:224Ownership#●●●#●●●
HeartBeam, Inc.
HeartBeam, Inc. insider Willem Elfrink filed a Form 4 on October 9, 2026, reporting a change in beneficial ownership of securities effective October 2, 2026. This filing serves as an official record of the insider's equity transaction.…more
$0.3989+1.19%vs prev closeDetected5m · 30m · 60m · Next dayPLUSView filingShare
- 10.9After-hours26.10.10 05:224Ownership
HeartBeam, Inc.
This is a Form 4 filing reported by Richard Ferrari of HeartBeam, Inc. as of October 2, 2026. The filing details a change in the insider's beneficial ownership of securities, providing transparency regarding corporate governance and insider trading activities.…more
$0.3989+1.19%vs prev closeView filingShare - 10.9After-hours26.10.10 05:224Ownership
HeartBeam, Inc.
Insider Michael R. Jaff of HeartBeam, Inc. reported a change in beneficial ownership of securities effective October 2, 2026. This filing serves as the official Form 4 submission regarding the insider's equity transaction.…more
$0.3989+1.19%vs prev closeView filingShare
9 more filings
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report
News
GlobeNewswire- 4d agoPre-market26.10.21 21:40#●●●#●●●
HeartBeam Completes Enrollment for HEADSTART-ACS Study Ahead of Schedule…more
HeartBeam has finished patient enrollment for its 486-patient cardiac study in Indonesia earlier than planned. The company is currently analyzing data as it prepares for a pivotal U.S. study scheduled for the first quarter of 2027.…more
$0.3989+1.19%vs prev closeDetected5m · 30m · 60m · Next dayPLUSShareBenzinga
- 10.15Pre-market26.10.15 21:37
●●●●●●●● ●●●●● ●●●●●●
HeartBeam has joined a global research consortium alongside leaders like Philips and Medtronic to participate in the EU-funded EXIT-CVD project. The company will lead a study evaluating its 3D ECG technology for early detection of cardiac events in high-risk patients.…more
$0.3989+1.19%vs prev closeShareBenzinga - 10.5Regular26.10.06 02:46
●●●●●●●● ●●●●● ●●●●●●
HeartBeam's at-home cardiac assessment system has received FDA Breakthrough Device Designation, enabling expedited regulatory review and potential faster Medicare reimbursement. This milestone, supported by positive clinical data, paves the way for the company to initiate pivotal studies for market clearance.…more
$0.3989+1.19%vs prev closeShareBenzinga
2 more news items
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report